Nuclear Medicine Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Nuclear Medicine Market Trends and Insights

Rising Burden of Targeted Diseases Drives Precision Diagnostics

Cancer incidence reached 2 million new U.S. cases in 2025, while cardiovascular disease remained the principal cause of global mortality, pushing cardiology departments to replace stress-only perfusion studies with hybrid PET-CT viability scans that guide revascularization.^{[1]American College of Cardiology, “2025 Nuclear Cardiology Guidelines,” acc.org} The World Health Organization reports that neurological disorders affect 1 in 3 people worldwide, spurring health systems to install cyclotrons and train nuclear-medicine physicians to manage the rising caseload. FDA and EMA companion-diagnostic mandates for targeted oncology drugs embed imaging into treatment algorithms and secure recurring procedure volumes. The combined disease burden, therefore, anchors long-term growth of the nuclear medicine market. Investments in public screening programs and research grants further reinforce demand visibility. As a result, cyclotron vendors and radiopharmacy operators are expanding capacity in major metropolitan areas and secondary cities alike.

Targeted Radiotherapy Adoption Reshapes Treatment Paradigms

Peptide receptor radionuclide therapy using lutetium-177 DOTATATE achieved a 79% disease-control rate in neuroendocrine tumor trials, eclipsing chemotherapy benchmarks and prompting guideline inclusion in the United States and Europe. Medicare’s 2025 coverage expansion for lutetium-177 PSMA-617 extended overall survival by 4 months in metastatic prostate cancer, triggering hospital investment in purpose-built therapy suites. Alpha-emitters such as radium-223 deliver high-linear-energy transfer over short ranges, reducing bone-marrow toxicity and appealing to oncologists treating frail patients. Theranostic pairs linking gallium-68 imaging to lutetium-177 therapy enable real-time dosimetry and limit unnecessary cycles, translating into lower overall care costs. Reimbursement parity between external-beam radiation and radiopharmaceutical therapy in Germany and France removes a historical barrier and accelerates European adoption.

Imaging Modality Advances Enhance Diagnostic Precision

Digital time-of-flight PET detectors improve signal-to-noise ratios by 40% and detect lesions as small as 5 mm, halving scan times and increasing scanner utilization.^{[2]Siemens Healthineers, “Digital PET Technology Whitepaper,” siemens-healthineers.com} Hybrid PET-MRI systems fuse metabolic and anatomical data without additional radiation, driving uptake in pediatric oncology and brain tumor imaging. Solid-state SPECT cameras with cadmium-zinc-telluride crystals double sensitivity over sodium-iodide systems, enabling lower doses for vulnerable populations. Portable gamma cameras now support intraoperative sentinel-node mapping, shortening surgical time and improving oncologic outcomes. Machine-learning algorithms trained on 500,000 PET scans auto-segment tumors, reducing inter-observer variability in multicenter trials.

Expansion of Non-Reactor Mo-99 Production Mitigates Supply Risk

NorthStar Medical Radioisotopes’ neutron-capture facility in Wisconsin produces 3,000 6-day curies of molybdenum-99 weekly without highly enriched uranium, diversifying North American supply. BWXT Medical’s photonuclear process yields carrier-free Mo-99, improving technetium-99m generator performance and extending shelf life by 20%. Australia’s OPAL reactor supplies 25% of global Mo-99 and shortens delivery times within Southeast Asia. Harmonized IAEA shipping standards remove redundant import permits, accelerating cross-border distribution. Stabilized Mo-99 output reduces price volatility and procedure cancellations for imaging centers, bolstering the nuclear medicine market.

Complex Multi-Agency Regulatory Approval Delays Market Entry

Radiopharmaceuticals must navigate separate FDA, EMA, and national pathways, each demanding extensive chemistry-manufacturing datasets and radiation dosimetry studies, extending timelines to 24 months and costing USD 50 million per compound. Divergent pediatric investigation requirements add further studies even when adult indications dominate, delaying European launches. Concordance data for theranostic companion diagnostics increase regulatory complexity, while long-term safety registries stretch smaller developers’ resources. These barriers consolidate innovation among large pharmaceutical firms and slow the pace of new entrants into the nuclear medicine industry.

Short Half-Life Isotopes Impose Logistical Constraints

Fluorine-18’s 110-minute half-life requires cyclotron proximity within a two-hour flight radius, limiting access in low-density geographies and increasing reliance on expensive charter flights.^{[3]International Atomic Energy Agency, “Radioisotope Transport Guidelines,” iaea.org} Technetium-99m generators decay 0.5% per hour, creating inventory challenges for hospitals with variable scan volumes. Gallium-68 generators lose activity over 12 months, necessitating frequent replacements that disrupt schedules. Cold-chain failures during transit can render isotopes unusable, particularly in tropical climates with weak logistics infrastructure. These constraints spur interest in longer-lived isotopes like copper-64 and zirconium-89, yet regulatory approval remains several years away.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Therapeutics Outpace Diagnostics on Theranostic Momentum

Diagnostics controlled 76.12% of revenue in 2025, supported by widespread SPECT myocardial perfusion and PET oncology protocols, yet therapeutics are projected to grow at 15.45% CAGR through 2031 as hospitals embrace lutetium-177 and actinium-225 regimens. This pivot will lift therapeutics’ contribution to the nuclear medicine market size, while diagnostics maintain a foundational role in patient selection and follow-up. SPECT preserves share in cardiology and bone imaging because of lower scanner costs, but PET continues to win oncology and neurology volumes due to superior resolution and quantification accuracy. Alpha-emitter doses command premium prices (USD 30,000 versus USD 8,000 for beta-emitters), reflecting their ability to eradicate radio-resistant tumors with fewer cycles. Beta-emitters such as yttrium-90 and lutetium-177 dominate liver and neuroendocrine tumor therapy, underpinned by robust safety data. Brachytherapy isotopes, including iodine-125, show flat growth as robotic surgery and external-beam modalities advance.

Therapeutic growth will lift pharmacy revenues and drive capital expenditure on hot cells, shielded infusion suites, and dosimetry software. Suppliers that bundle diagnostic tracers with matched therapies will capture higher wallet share. As theranostics mature, integrated pathways will lower total care costs, reinforcing payer support and sustaining nuclear medicine market expansion.

By Radioisotope: Lutetium-177 Surges on PSMA Therapy Adoption

Technetium-99m retained a 43.28% share in 2025, driven by high-volume cardiology and bone scans. Yet lutetium-177 doses are rising at a 14.31% CAGR as PSMA therapy enters mainstream oncology practice, expanding the nuclear medicine market share of therapeutic isotopes. Fluorine-18 remains the backbone of PET imaging, but novel tracers targeting PSMA and fibroblast activation protein expand its utility beyond oncology into inflammation and cardiac fibrosis. Iodine-131 remains standard for thyroid disorders, though usage plateaus amid surgery advances and oral kinase inhibitors. 

Emerging isotopes such as gallium-68 and copper-64 are gaining momentum at academic centers running early-access programs, paving the way for broader adoption once supply chains mature. Suppliers investing in flexible production line configurations will be best positioned to meet demand variance across isotope classes.

By Application: Neurology Accelerates on Alzheimer’s Diagnostic Demand

Oncology accounted for 41.84% of revenue in 2025; however, neurology is expected to post a 14.29% CAGR as amyloid-beta and tau PET tracers enter routine Alzheimer’s workups. Cardiology volumes stabilize as stress-only SPECT protocols reduce isotope consumption without sacrificing diagnostic value. Endocrinology applications grow in line with the overall nuclear medicine market, benefiting from readily available iodine-123 and gallium-68 DOTATATE. Orthopedic bone scintigraphy faces pressure from MRI in younger cohorts but remains relevant for elderly patients with metal implants. Infection and renal imaging remain niche but indispensable in complex cases, preserving a diversified procedure mix and underpinning the nuclear medicine market.

By End User: Specialized Radiopharmacies Capture Logistics Value

Hospitals generated 49.69% of 2025 sales by virtue of embedded radiopharmacies and research programs, yet specialized radiopharmacies are expanding at a 13.61% CAGR through 2031. Centralized compounding reduces on-site radiation hazards, slashes capital costs, and ensures unit-dose delivery within the half-life windows of isotopes. Imaging centers increasingly outsource tracer supply while deploying mobile PET-CT units to reach rural populations. Research institutes account for 8% of isotope volumes as they validate new tracers ahead of commercialization. Ambulatory surgical centers are beginning to adopt portable gamma cameras for radioguided oncologic procedures, creating incremental demand for low-volume isotopes. This evolving channel mix will shape procurement strategies and vendor partnerships across the nuclear medicine industry.

Geography Analysis

North America led with 39.43% revenue share in 2025, supported by over 2,500 PET-CT scanners and Medicare coverage for 18 PET tracers. The United States hosts 120 hospitals offering lutetium-177 PSMA therapy and 40 actinium-225 clinical-trial sites, accelerating regulatory approvals and fostering research synergies. Canada’s transition to non-reactor Mo-99 production mitigates prior supply disruptions, while Mexico’s public-private scanner installations extend access to its 130 million population.

Europe boasts high PET penetration, with Germany operating 180 cyclotrons that enable same-day fluorine-18 deliveries to 95% of residents. National health systems reimburse amyloid PET and gallium-68 PSMA, reinforcing procedural volumes. Italy and Spain invest in theranostic centers that consolidate diagnostics and therapy under one roof, lowering care costs. Poland and Hungary modernize legacy gamma cameras, lifting demand for updated isotopes and software.

Asia-Pacific is the fastest-growing region at 14.56% CAGR, led by China’s installation of 300 PET-CT scanners in 2025 and India’s expansion of cyclotron sites to 27 by 2027. Japan’s aging population drives Alzheimer’s and cardiac viability imaging, with national insurance coverage since 2024. South Korea subsidizes PET-CT equipment for rural hospitals, cutting wait times to 5 days. Australia’s regulatory approvals for copper-64 and zirconium-89 tracers position it as a regional clinical-trial hub, while ASEAN nations form shared radiopharmacy networks to overcome scale challenges.

Regulatory Landscape

Nuclear medicine radiopharmaceuticals are handled under tightly controlled drug and radiation-safety regimes, with added complexity when products are treated as drug-device combinations. In the United States, the FDA Office of Combination Products determines jurisdiction and requires compliance with drug CGMP (21 CFR 210/211) alongside device quality-system requirements (21 CFR 820), or a streamlined approach under 21 CFR Part 4 for combination products, which increases documentation and inspection readiness demands for radiopharmacies and manufacturers.

In Europe, the regulatory pathway depends on the principal mode of action, with integral drug-device combinations typically reviewed within the medicinal products framework when pharmacological action is primary, while Medical Device Regulation (EU) 2017/745 can trigger additional Notified Body interactions for certain configurations. For radiation protection, IAEA Safety Standards (including SSG-46) provide a widely referenced baseline for safe medical use of ionizing radiation. A June 2025 IAEA technical meeting also highlighted gaps around updated guidance for modern radionuclides and pediatric nuclear medicine, including the need for more harmonized patient discharge approaches after radionuclide therapies.

Value Chain Analysis

The nuclear medicine value chain begins with isotope production, using reactor and non-reactor routes for key medical isotopes plus cyclotron-based production for PET isotopes. This is followed by target processing, radiochemical purification, radiolabeling and finished-dose manufacturing under GMP, quality control and batch release, and then time-critical distribution to hospitals, imaging centers, and specialized radiopharmacies. Because many isotopes have short half-lives, last-mile logistics and scheduling become a main source of value, with specialized couriers and regional production hubs used to protect delivered activity and reduce waste.

Bottlenecks tend to cluster around reliable isotope availability, specialized hot-cell and shielding infrastructure, and qualified radiopharmacy operations that can support multi-product GMP compliance. Suppliers and service providers are therefore adding capacity and moving toward vertical integration across production and distribution, including SHINE Technologies completing its acquisition of Lantheus SPECT manufacturing assets (including the North Billerica facility) in January 2026, and Cardinal Health adding a high-capacity actinium-225 production line at its Center for Theranostics Advancement in Indianapolis in April 2026. In Europe, Curium’s June 2026 plan to add a new production line at Saclay, France for Lu-177-PSMA-I&T aims to align upstream isotope capability with downstream clinical demand for theranostics.

Market Opportunities and Future Outlook

Expanded licensed production and simplified compliance pathways are becoming a focal opportunity set, since they support scale-up for hospitals and specialized radiopharmacies. In May 2026, the US Nuclear Regulatory Commission proposed the rule "Modernizing NRC Regulations for Byproduct Material Use" to ease the regulatory burden on radiopharmaceutical licensees, and this modernization creates room for faster site onboarding, standardized operating models, and multi-site distribution networks.

Procurement and partnering opportunities are also opening through supply expansion and localization efforts across both diagnostics and therapeutics. Several 2026 actions illustrate the direction of travel: Curium announced an over EUR 32 million investment (June 2026) to add Lutetium-177 production capacity at Saclay, France; IBA signed multi-site cyclotron agreements in India (February 2026, with Shreeji) and in the United States (March 2026, with Telix) to broaden PET radiopharmaceutical manufacturing footprints; and RadioMedix reported FDA approval for Ga-68 PSMA-11 (June 2026), supporting broader access to prostate cancer PET diagnostics. Taken together, these moves support growth for integrated suppliers offering isotope production, radiolabeling, and distribution as bundled services, while also creating demand pull for CDMOs and specialized radiopharmacies tied to therapy-suite buildouts and expanding tracer menus.